Genmab A/S (CPH:GMAB)
Denmark
· Delayed Price · Currency is DKK 1,458.50
+21.00 (1.46%)
Aug 14, 2025, 4:59 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Reimbursement | 138.35M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Reimbursement Growth | -28.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Milestone | 138.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Milestone Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| License | 277.81K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 242.11M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 93.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| DARZALEX Royalties | 1.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| DARZALEX Royalties Growth | 21.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kesimpta Royalties | 308.65M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kesimpta Royalties Growth | 37.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TEPEZZA Royalties | 102.37M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TEPEZZA Royalties Growth | -0.45% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Royalties | 65.42M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Royalties Growth | 51.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration | 60.15M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Collaboration Growth | 28.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Net Product Sales | 242.11M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Net Product Sales Growth | 93.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| J&J | 2.00B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| J&J Growth | 20.29% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novartis | 391.99M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Novartis Growth | 66.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioNTech | 120.71M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioNTech Growth | -32.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pfizer | 74.04M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pfizer Growth | 22.64% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaboration Partner | 277.81K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Collaboration Partner Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Roche | 102.93M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Roche Growth | 1.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AbbVie | 54.73M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| AbbVie Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Denmark | 2.75B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Denmark Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States | 125.29M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan | 116.82M |
Log In |
Log In |
Log In |
Log In | Upgrade
|